Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study

	EASL 2026 May 26-30 Barcelona Ed Gane1,